Ypsomed will establish its first manufacturing facility in the United States. The company has selected Holly Springs in Wake County, North Carolina, as the location and will invest around CHF 200 million in a first phase.
This is another milestone in Ypsomed’s global growth strategy, bringing the company closer to its customers and enabling it to serve local markets directly. From end of 2027 onwards, the new site in Holly Springs will supply products for the U.S. market.
The North American manufacturing facility will expand Ypsomed’s production capacity and strengthen its global partnerships. To accelerate its expansion, Ypsomed is buying a building with 15,000 square meters (>160,000 sq ft) with an option for further expansion. The company is initially expecting to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
"We have deliberately chosen Holly Springs, a location at the heart of our industry, close to our customers," Ypsomed CEOSimon Michel said. "The cooperative approach of the local authorities, the excellent infrastructure and the proximity to top-tier universities provide ideal conditions for our future growth. This environment will allow us to attract the skilled workforce we need and to further strengthen our position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the U.S. healthcare market."
